Invesco
ANTX icon

Invesco’s AN2 Therapeutics ANTX Stock Holding History

Invesco’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67K Buy
+13,839
New +$59.5K ﹤0.01% 3773
2024
Q1 		– Sell
-157,891
Closed -$3.24M – 3864
2023
Q4 		$3.24M Sell
157,891
-30,006
-16% -$502K ﹤0.01% 2436
2023
Q3 		$3.02M Buy
+187,897
New +$2.13M ﹤0.01% 2441

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Invesco's ANTX Position: Q2 2026 in Review

Invesco opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 13,839 shares worth $67K. The stake represents ﹤0.01% of the portfolio and ranks #3773 among its holdings. This is a return to the name: Invesco previously reported a position in ANTX as recently as Q4 2023.

Invesco first reported a position in ANTX in Q3 2023 and has held it in 3 quarters since. The position peaked at $3.24M in Q4 2023. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Invesco held 13,839 shares of AN2 Therapeutics worth $67K as of Q2 2026.
  • AN2 Therapeutics was a new Invesco position in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3773 holding.
  • Invesco first reported a position in AN2 Therapeutics in Q3 2023 and has held it in 3 quarters since.
  • Invesco's AN2 Therapeutics position peaked at $3.24M in Q4 2023.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.